nach oben

Erschienen in:

12.06.2023 | Arzneimitteltherapie bei Älteren | CME

Kardiovaskuläre Pharmakotherapie im Alter

verfasst von: Prof. Dr. Martin Schulz, Dietmar Trenk, Ulrich Laufs

Erschienen in: Herz | Ausgabe 4/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Kardiovaskuläre Erkrankungen stellen die häufigste Ursache für Behinderung und Tod dar. Evidenzbasierte Pharmakotherapie ist die Basis zur erfolgreichen Therapie der Volkskrankheiten Hypertonie, Herzinsuffizienz, koronare Herzkrankheit und Vorhofflimmern. Der Anteil älterer Menschen mit mehreren Krankheiten (Multimorbidität), die 5 oder mehr Arzneimittel täglich benötigen (Polymedikation), nimmt stetig zu. Die Evidenz zur Wirksamkeit und Sicherheit von Arzneimitteln bei diesen Menschen ist begrenzt, da diese häufig von klinischen Studien ausgeschlossen oder unterrepräsentiert sind. Leitlinien fokussieren zudem größtenteils auf einzelne Krankheiten und behandeln nur gelegentlich die Herausforderungen in der Pharmakotherapie älterer multimorbider Patienten mit Multimedikation. Dieser Artikel beschreibt die Chancen und die Besonderheiten der Pharmakotherapie bei Hypertonie, chronischer Herzinsuffizienz und Fettstoffwechselstörungen sowie der antithrombotischen Therapie bei (Hoch‑)Betagten.

Kaski JC, Tamargo J, Savarese G (2020) Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. Eur Heart J Cardiovasc Pharmacother 6:277–279. https://doi.org/10.1093/ehjcvp/pvaa090 CrossRefPubMed

Tamargo J, Kjeldsen KP, Delpón E et al (2022) Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European society of cardiology working group on cardiovascular pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 8:406–419. https://doi.org/10.1093/ehjcvp/pvac005 CrossRefPubMed

Zhang W, Zhang S, Deng Y et al (2021) Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 385:1268–1279. https://doi.org/10.1056/NEJMoa2111437 CrossRefPubMed

Beckett NS, Peters R, Fletcher AE et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898. https://doi.org/10.1056/NEJMoa0801369 CrossRefPubMed

Williamson JD, Supiano MA, Applegate WB et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 315:2673–2682. https://doi.org/10.1001/jama.2016.7050 CrossRefPubMedPubMedCentral

Flather MD, Shibata MC, Coats AJS et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225. https://doi.org/10.1093/eurheartj/ehi115 CrossRefPubMed

Leitliniengruppe Hessen (2021) S3-Leitlinie Multimedikation, Langfassung. https://www.degam.de/degamleitlinien-379.html. Zugegriffen: 3. Febr. 2023

Jaehde U, Radziwill R, Kloft C (2017) Klinische Pharmazie: Grundlagen und Anwendung, 4. Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart

Lappe V, Dinh TS, Harder S et al (2022) Multimedication guidelines: assessment of the size of the target group for medication review and description of the frequency of their potential drug safety problems with routine data. Pharmacoepidemiology 1:12–25. https://doi.org/10.3390/pharma1010002 CrossRef

10.

Kwak MJ, Cheng M, Goyal P et al (2022) Medication complexity among older adults with HF: how can we assess better? Drugs Aging 39:851–861. https://doi.org/10.1007/s40266-022-00979-2 CrossRefPubMed

11.

Correale M, Paolillo S, Mercurio V et al (2020) Comorbidities in chronic heart failure: an update from Italian society of cardiology (SIC) working group on heart failure. Eur J Intern Med 71:23–31. https://doi.org/10.1016/j.ejim.2019.10.008 CrossRefPubMed

12.

Botermann L, Monzel K, Krueger K et al (2016) Evaluating patients’ comprehensibility of a standardized medication plan. Eur J Clin Pharmacol 72:1229–1237. https://doi.org/10.1007/s00228-016-2082-5 CrossRefPubMed

13.

Ewen S, Baumgarten T, Rettig-Ewen V et al (2015) Analyses of drugs stored at home by elderly patients with chronic heart failure. Clin Res Cardiol 104:320–327. https://doi.org/10.1007/s00392-014-0783-2 CrossRefPubMed

14.

Schulz M, Griese-Mammen N, Anker SD et al (2019) Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail 21:1012–1021. https://doi.org/10.1002/ejhf.1503 CrossRefPubMed

15.

Custodis F, Rohlehr F, Wachter A et al (2016) Medication knowledge of patients hospitalized for heart failure at admission and after discharge. Patient Prefer Adherence 10:2333–2339. https://doi.org/10.2147/PPA.S113912 CrossRefPubMedPubMedCentral

16.

Pantuzza LL, Ceccato MDGB, Silveira MR et al (2017) Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. Eur J Clin Pharmacol 73:1475–1489. https://doi.org/10.1007/s00228-017-2315-2 CrossRefPubMed

17.

Wimmer BC, Cross AJ, Jokanovic N et al (2017) Clinical outcomes associated with medication regimen complexity in older people: a systematic review. J Am Geriatr Soc 65:747–753. https://doi.org/10.1111/jgs.14682 CrossRefPubMed

18.

Alves-Conceição V, Rocha KSS, Silva FVN et al (2018) Medication regimen complexity measured by MRCI: a systematic review to identify health outcomes. Ann Pharmacother 52:1117–1134. https://doi.org/10.1177/1060028018773691 CrossRefPubMed

19.

Choudhry NK, Kronish IM, Vongpatanasin W et al (2022) Medication adherence and blood pressure control: a scientific statement from the American heart association. Hypertension 79:e1–e14. https://doi.org/10.1161/HYP.0000000000000203 CrossRefPubMed

20.

Alves-Conceição V, Rocha KSS, Silva FVN et al (2020) Are clinical outcomes associated with medication regimen complexity? A systematic review and meta-analysis. Ann Pharmacother 54:301–313. https://doi.org/10.1177/1060028019886846 CrossRefPubMed

21.

Burnier M, Polychronopoulou E, Wuerzner G (2020) Hypertension and drug adherence in the elderly. Front Cardiovasc Med 7:49. https://doi.org/10.3389/fcvm.2020.00049 CrossRefPubMedPubMedCentral

22.

Krueger K, Botermann L, Schorr SG et al (2015) Age-related medication adherence in patients with chronic heart failure: a systematic literature review. Int J Cardiol 184:728–735. https://doi.org/10.1016/j.ijcard.2015.03.042 CrossRefPubMed

23.

Hughes D, Judge C, Murphy R et al (2020) Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA 323:1934–1944. https://doi.org/10.1001/jama.2020.4249 CrossRefPubMed

24.

Mann N‑K, Mathes T, Sönnichsen A et al (2023) Potentially inadequate medications in the elderly: PRISCUS 2.0—first update of the PRISCUS list. Dtsch Arztebl Int 120:3–10. https://doi.org/10.3238/arztebl.m2022.0377 CrossRefPubMedPubMedCentral

25.

Pazan F, Weiß C, Wehling M (2021) FORTA—fit fOR the aged. https://www.umm.uni-heidelberg.de/experimentelle-pharmakologie/research/gruppe-wehling/. Zugegriffen: 3. Febr. 2023

26.

Forouzanfar MH, Afshin A, Alexander LT et al (2016) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet 388:1659–1724. https://doi.org/10.1016/S0140-6736(16)31679-8 CrossRef

27.

Neuhauser HK, Adler C, Rosario AS et al (2015) Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens 29:247–253. https://doi.org/10.1038/jhh.2014.82 CrossRefPubMed

28.

Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339 CrossRefPubMed

29.

Mühlbauer V, Dallmeier D, Brefka S et al (2019) The pharmacological treatment of arterial hypertension in frail, older patients—a systematic review. Dtsch Arztebl Int 116:23–30. https://doi.org/10.3238/arztebl.2019.0023 CrossRefPubMedPubMedCentral

30.

Bogaerts JMK, von Ballmoos LM, Achterberg WP et al (2022) Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases. Age Ageing 51:afab192. https://doi.org/10.1093/ageing/afab192 CrossRefPubMed

31.

Schwinger RHG (2018) Medikamentöse Therapie kardiologischer Erkrankungen im Alter (cardiovascular medication in elderly patients). Dtsch Med Wochenschr 143:236–243. https://doi.org/10.1055/s-0043-108475 CrossRefPubMed

32.

Benetos A, Petrovic M, Strandberg T (2019) Hypertension management in older and frail older patients. Circ Res 124:1045–1060. https://doi.org/10.1161/CIRCRESAHA.118.313236 CrossRefPubMed

33.

Karayiannis CC (2022) Hypertension in the older person: is age just a number? Intern Med J 52:1877–1883. https://doi.org/10.1111/imj.15949 CrossRefPubMedPubMedCentral

34.

Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125:882–887.e1. https://doi.org/10.1016/j.amjmed.2011.12.013 CrossRefPubMed

35.

Gupta P, Patel P, Štrauch B et al (2017) Risk factors for nonadherence to antihypertensive treatment. Hypertension 69:1113–1120. https://doi.org/10.1161/HYPERTENSIONAHA.116.08729 CrossRefPubMed

36.

Lee EKP, Poon P, Yip BHK et al (2022) Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc 11:e26582. https://doi.org/10.1161/JAHA.122.026582 CrossRefPubMedPubMedCentral

37.

Rea F, Savaré L, Franchi M et al (2021) Adherence to treatment by initial antihypertensive mono and combination therapies. Am J Hypertens 34:1083–1091. https://doi.org/10.1093/ajh/hpab083 CrossRefPubMed

38.

Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:399–407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816 CrossRefPubMed

39.

Rea F, Corrao G, Merlino L et al (2018) Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 39:3654–3661. https://doi.org/10.1093/eurheartj/ehy420 CrossRefPubMed

40.

Mahfoud F, Kieble M, Enners S et al (2023) Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clin Res Cardiol 112:197–202. https://doi.org/10.1007/s00392-022-01993-5 CrossRefPubMed

41.

KBV (2023) Medikationskatalog Hypertonie. https://www.kbv.de/html/medikationskatalog.php. Zugegriffen: 3. Febr. 2022

42.

Trenk D (2023) Chronische Herzinsuffizienz. Medikamentöse Therapie im Umbruch. Pharm Ztg 168:148–158

43.

Arzneimittelkommission der Deutschen Apotheker, Arzneimittelkommission der deutschen Ärzteschaft, Bundesarbeitsgemeinschaft Selbsthilfe et al (2019) NVL Chronische Herzinsuffizienz – Langfassung, 3. Aufl.

44.

McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368 CrossRefPubMed

45.

Abdin A, Schulz M, Riemer U et al (2022) Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail. https://doi.org/10.1002/ehf2.14097 CrossRefPubMedPubMedCentral

46.

Packer M, McMurray JJV (2021) Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail 23:882–894. https://doi.org/10.1002/ejhf.2149 CrossRefPubMed

47.

Sharma A, Verma S, Bhatt DL et al (2022) Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci 7:504–517. https://doi.org/10.1016/j.jacbts.2021.10.018 CrossRefPubMedPubMedCentral

48.

Gilstrap L, Zipkin RJ, Barnes JA et al (2022) Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5‑year survival in older patients with heart failure with reduced ejection fraction: a decision analysis approach. Am Heart J 250:23–28. https://doi.org/10.1016/j.ahj.2022.04.007 CrossRefPubMed

49.

Gosch M (2022) Pharmakologische Therapie kardiologischer Erkrankungen im Alter: Geriatrische Perspektive. Z Gerontol Geriatr 55:471–475. https://doi.org/10.1007/s00391-022-02084-w CrossRefPubMed

50.

Evans M, Morgan AR, Davies S et al (2022) The role of sodium-glucose co-transporter‑2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing 51:afac201. https://doi.org/10.1093/ageing/afac201 CrossRefPubMedPubMedCentral

51.

Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461. https://doi.org/10.1056/NEJMoa2107038 CrossRefPubMed

52.

Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098. https://doi.org/10.1056/NEJMoa2206286 CrossRefPubMed

53.

Vaduganathan M, Claggett BL, Jhund PS et al (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121–128. https://doi.org/10.1016/S0140-6736(20)30748-0 CrossRefPubMed

54.

Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007 CrossRefPubMed

55.

Kato ET, Giugliano RP, Ruff CT et al (2016) Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 5:e3432. https://doi.org/10.1161/JAHA.116.003432 CrossRefPubMedPubMedCentral

56.

Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. https://doi.org/10.1056/NEJMoa1107039 CrossRefPubMed

57.

Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477. https://doi.org/10.1093/eurheartj/ehz425 CrossRefPubMed

58.

Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1 CrossRefPubMed

59.

Patrono C, García Rodríguez LA, Landolfi R et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383. https://doi.org/10.1056/NEJMra052717 CrossRefPubMed

60.

Neumann F‑J, Sousa-Uva M, Ahlsson A et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87–165. https://doi.org/10.1093/eurheartj/ehy394 CrossRefPubMed

61.

Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034. https://doi.org/10.1016/S0140-6736(17)30397-5 CrossRefPubMed

62.

Laufs U, Weingärtner O, Kassner U et al (2022) State of the Art: Therapie mit Statinen. Dtsch Med Wochenschr 147:62–68. https://doi.org/10.1055/a-1516-2471 CrossRefPubMed

63.

Gencer B, Marston NA, Im K et al (2020) Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396:1637–1643. https://doi.org/10.1016/S0140-6736(20)32332-1 CrossRefPubMedPubMedCentral

64.

Cholesterol Treatment Trialists’ Collaboration (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 393:407–415. https://doi.org/10.1016/S0140-6736(18)31942-1 CrossRef

65.

Orkaby AR, Driver JA, Ho Y‑L et al (2020) Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324:68–78. https://doi.org/10.1001/jama.2020.7848 CrossRefPubMedPubMedCentral

66.

Giral P, Neumann A, Weill A et al (2019) Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 40:3516–3525. https://doi.org/10.1093/eurheartj/ehz458 CrossRefPubMedPubMedCentral

67.

Katzmann JL, Kieble M, Enners S et al (2022) Trends in ezetimibe prescriptions as monotherapy or fixed-dose combination in Germany 2012–2021. Front Cardiovasc Med 9:912785. https://doi.org/10.3389/fcvm.2022.912785 CrossRefPubMedPubMedCentral

Titel: Kardiovaskuläre Pharmakotherapie im Alter
verfasst von: Prof. Dr. Martin Schulz
Dietmar Trenk
Ulrich Laufs
Publikationsdatum: 12.06.2023
Verlag: Springer Medizin
Schlagwörter: Arzneimitteltherapie bei Älteren
Polymedikation bei geriatrischen Patienten
Herzerkrankungen und Komorbidität
Pharmakokinetik
Pharmakodynamik
Vorhofflimmern
Hypertonie
Herzinsuffizienz
Koronare Herzerkrankung
Orale Antikoagulanzien
Erschienen in: Herz / Ausgabe 4/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-023-05191-5

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Pulmonary hypertension

Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension

Outcome of a polymer-free drug-coated coronary stent in bifurcation lesions—Pilot registry with serial OCT imaging

Chronic thromboembolic pulmonary hypertension—medical, interventional, and surgical therapy

Right ventricular failure in pulmonary hypertension: recent insights from experimental models

Correlation between decreased plasma miR-29a and vascular endothelial injury induced by hyperlipidemia